Fig. 5: ProAgio decreases CD31-positive cells and increases differentiated LSEC in fibrotic liver.
From: Targeting integrin αvβ3 by a rationally designed protein for chronic liver disease treatment
a Representative images of IF staining of SE-1, an antibody recognizing a differentiated LSEC marker, and b quantitation of SE-1 IF staining of liver tissue sections from mice treated with indicated agents. The quantity of SE-1 IF is presented as a fold change in SE-1 stain compared with that of non-fibrotic mice (normal). c Representative images of IHC stain of CD31 and d quantitation of CD31 IHC stain of liver tissue sections from mice treated with indicated agents. The quantity of CD31 IHC is presented as a fold change in CD31 stain compared with that of non-fibrotic mice (normal). e Representative images of IF staining of CD31 (Red) and cleaved caspase-3 (green) and the overlay of co-stains (Yellow) of liver sections from mice treated with indicated agents. Scale bars in a, c, and e show 100 µm. Error bars in b and d are standard deviations of measurements of 10 mice. Normal in a–d are the mice without fibrosis induction and treatment. *P < 0.05; **P < 0.01, ***P < 0.001.
